Role of zonisamide in advanced Parkinson’s disease: a randomized placebo-controlled study

被引：0
|
作者：
Mohamed Essam
Eman Hamid
Eman Abushady
Mahmoud El-Balkimy
Angelo Antonini
Ali Shalash
机构：
[1] Ain Shams University,Department of Neurology, Faculty of Medicine
[2] University of Padua,Parkinson and Movement Disorders Unit, Study Center for Neurodegeneration (CESNE), Department of Neuroscience
来源：
Neurological Sciences | 2024年 / 45卷
关键词：
Zonisamide; Parkinson̕ s disease; Wearing off; Nonmotor symptoms; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1725 / 1734
页数：9
相关论文
共 50 条
  • [31] A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ANAKINRA IN PATIENTS WITH STILL′S DISEASE
    Schanberg, L.
    Nigrovic, P.
    Cooper, A.
    Chatham, W.
    Akoghlanian, S.
    Singh, N.
    Rabinovich, E.
    Thatayatikom, A.
    Taxter, A.
    Hausmann, J.
    Zdravkovic, M.
    Ohlman, S.
    Andersson, H.
    Cederholm, S.
    Wiken, M.
    Schneider, R.
    De Benedetti, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1815 - 1816
  • [32] A Randomized, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain
    McElroy, Susan L.
    Winstanley, Erin
    Mori, Nicole
    Martens, Brian
    McCoy, Jessica
    Moeller, Dianna
    Guerdjikova, Anna I.
    Keck, Paul E., Jr.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (02) : 165 - 172
  • [33] EXPRESS: A prospective, placebo-controlled study of rivastigmine in Parkinson's disease dementia
    Herrmann, M
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 264 - 265
  • [34] Rivastigmine for mild cognitive impairment in Parkinson's disease: A placebo-controlled study
    Weintraub, D.
    Mamikonyan, E.
    Xie, S. X.
    Melvin, E.
    MOVEMENT DISORDERS, 2015, 30 : S136 - S136
  • [35] Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study
    Lagalla, Giovanni
    Millevolte, Marzia
    Capecci, Marianna
    Provinciali, Leandro
    Ceravolo, Maria Gabriella
    MOVEMENT DISORDERS, 2006, 21 (05) : 704 - 707
  • [36] Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study
    Asako Yoritaka
    Yasuko Kobayashi
    Tetsuo Hayashi
    Shinji Saiki
    Nobutaka Hattori
    Neurological Sciences, 2021, 42 : 4767 - 4770
  • [37] Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson's disease: a pilot study
    Yoritaka, Asako
    Kobayashi, Yasuko
    Hayashi, Tetsuo
    Saiki, Shinji
    Hattori, Nobutaka
    NEUROLOGICAL SCIENCES, 2021, 42 (11) : 4767 - 4770
  • [38] Donepezil for dementia in Parkinson's disease: A randomized, double-blind, placebo-controlled, crossover study.
    Ravina, B
    Putt, M
    Siderowf, A
    Farrar, JT
    Gillespie, M
    Crawley, A
    Fernandez, H
    Treischmann, M
    Reichwein, S
    Simuni, T
    MOVEMENT DISORDERS, 2004, 19 (09) : 1132 - 1133
  • [39] Parkinson's disease - Improved function with GM1 ganglioside treatment in a randomized placebo-controlled study
    Schneider, JS
    Roeltgen, DP
    Mancall, EL
    Chapas-Crilly, J
    Rothblat, DS
    Tatarian, GT
    NEUROLOGY, 1998, 50 (06) : 1630 - 1636
  • [40] Clinical efficacy of istradefylline (KW-6002) in the treatment of Parkinson's disease: A randomized placebo-controlled study
    Mizuno, Y.
    Kuno, S.
    Yamamoto, M.
    Hasegawa, K.
    Kondo, T.
    MOVEMENT DISORDERS, 2009, 24 : S269 - S269
12345